Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands

Rob ter Heine; Geert Wj Frederix; Joost W Geenen; Anke M Hövels; Marco van Vulpen; Anko Kooistra; John Mh de Klerk; Haiko J Bloemendal

doi:10.2217/cer-2017-0026

Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands

Rob ter Heine, Geert Wj Frederix, Joost W Geenen, Anke M Hövels, Marco van Vulpen, Anko Kooistra, John Mh de Klerk, Haiko J Bloemendal

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIM: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs).

METHODS: We performed a bottom-up cost of illness study in The Netherlands.

RESULTS: A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039-9346, depending on care. These SREs had median costs of €200-1912.

CONCLUSION: Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.

Original language	English
Pages (from-to)	575-581
Number of pages	7
Journal	Journal of Comparative Effectiveness Research
Volume	6
Issue number	7
DOIs	https://doi.org/10.2217/cer-2017-0026
Publication status	Published - Oct 2017

Keywords

bone metastases
cost of illness
prostate cancer
radionuclide therapy
skeletal-related events

Access to Document

10.2217/cer-2017-0026

Cite this

@article{4574e2598ebb4e63b2aa25684769569c,

title = "Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands",

abstract = "AIM: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs).METHODS: We performed a bottom-up cost of illness study in The Netherlands.RESULTS: A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039-9346, depending on care. These SREs had median costs of €200-1912.CONCLUSION: Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.",

keywords = "bone metastases, cost of illness, prostate cancer, radionuclide therapy, skeletal-related events",

author = "{ter Heine}, Rob and Frederix, {Geert Wj} and Geenen, {Joost W} and H{\"o}vels, {Anke M} and {van Vulpen}, Marco and Anko Kooistra and {de Klerk}, {John Mh} and Bloemendal, {Haiko J}",

note = "Publisher Copyright: {\textcopyright} 2017 2017 Future Medicine Ltd.",

year = "2017",

month = oct,

doi = "10.2217/cer-2017-0026",

language = "English",

volume = "6",

pages = "575--581",

number = "7",

}

TY - JOUR

T1 - Cost of illness of metastatic prostate cancer

T2 - a perspective of costs for new treatment options in The Netherlands

AU - ter Heine, Rob

AU - Frederix, Geert Wj

AU - Geenen, Joost W

AU - Hövels, Anke M

AU - van Vulpen, Marco

AU - Kooistra, Anko

AU - de Klerk, John Mh

AU - Bloemendal, Haiko J

PY - 2017/10

Y1 - 2017/10

N2 - AIM: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs).METHODS: We performed a bottom-up cost of illness study in The Netherlands.RESULTS: A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039-9346, depending on care. These SREs had median costs of €200-1912.CONCLUSION: Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.

AB - AIM: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs).METHODS: We performed a bottom-up cost of illness study in The Netherlands.RESULTS: A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039-9346, depending on care. These SREs had median costs of €200-1912.CONCLUSION: Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.

KW - bone metastases

KW - cost of illness

KW - prostate cancer

KW - radionuclide therapy

KW - skeletal-related events

UR - http://www.scopus.com/inward/record.url?scp=85032743000&partnerID=8YFLogxK

U2 - 10.2217/cer-2017-0026

DO - 10.2217/cer-2017-0026

M3 - Article

C2 - 29091013

SN - 2042-6313

VL - 6

SP - 575

EP - 581

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

IS - 7

ER -

Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this